Iptakalim hydrochloride|cas:642407-63-4|西域试剂

Iptakalim hydrochloride,98.0%

产品编号：Bellancom-108069| CAS NO：642407-63-4| 分子式：C₉H₂₂ClN| 分子量：179.73

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-108069		￥1800.00	杭州北京（现货）
Bellancom-108069		￥2900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Iptakalim hydrochloride

产品介绍

Iptakalim hydrochloride 是亲脂性的对氨基化合物，是 ATP 敏感的钾通道 (K_ATP) 的开放剂，也是包含α₄β₂ 的烟碱乙酰胆碱受体 (nAChR)拮抗剂。

生物活性

Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (K_ATP) opener, as well as an α₄β₂-containing nicotinic acetylcholine receptor (nAChR) antagonist.

体外研究

Iptakalim (Ipt) hydrochloride has been shown to reverse pulmonary resistance vascular remodeling, inhibit proliferation of pulmonary arterial smooth muscle cells (PASMCs) and airway smooth muscle cells (ASMCs), as well as protect PAECs from pathological stimulation.
Iptakalim has an inhibitory effect on [Ca²⁺]cyt increase and the proliferation of pulmonary arterial SMCs induced by endothelin-1 through activation of K_ATP channels. Iptakalim (10 μM, 10 min) pretreatment of pulmonary arterial SMCs significantly prevents ransient ncrease of [Ca²⁺]cyt elicited by endothelin-1.
Iptakalim at he concentrations of 0.1, 1, and 10 AM lowered[3H]thymidine incorporation by 19.75±4.60% (n=10), 41.20±9.49% (n=10), and 54.74±10.11% (n=10), respectively, compared with that of cells treated only with endothelin-1.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Iptakalim (10-60 mg/kg) attenuates nicotine-evoked conditioned responding. Iptakalim also attenuates chamber activity in these nicotine test sessions.
. Iptakalim (60 mg/kg) pretreatment significantly reduced activity (LSD comparisons).
.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Thirty male Sprague-Dawley rats weighing 275-299 grams.
Dosage:	0, 10, 30, or 60 mg/kg.
Administration:	IP, 10 min before the start of a 4-min test session.
Result:	Decreased chamber activity. Dipper entries following pretreatment with 30 and 60 mg/kg Iptakalim were significantly lower than with 0 (saline) or 10 mg/kg iptakalim pretreatment (Tukey HSD tests).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Thirty male Sprague-Dawley rats weighing 275-299 grams.
Dosage:	0, 10, 30, or 60 mg/kg.
Administration:	IP, 10 min before the start of a 4-min test session.
Result:	Decreased chamber activity. Dipper entries following pretreatment with 30 and 60 mg/kg Iptakalim were significantly lower than with 0 (saline) or 10 mg/kg iptakalim pretreatment (Tukey HSD tests).

性状

Solid

溶解性数据

In Vitro:

H₂O : 25 mg/mL (139.10 mM; ultrasonic and warming and heat to 70°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.5639 mL	27.8195 mL	55.6390 mL
5 mM	1.1128 mL	5.5639 mL	11.1278 mL
10 mM	0.5564 mL	2.7820 mL	5.5639 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶